The role of the endogenous cannabinoid system in peripheral analgesia

Current Molecular Pharmacology

Volumn 2, Issue 1, 2009, Pages 134-139

  Guindon, Josée ^a   Beaulieu, Pierre ^b  

^a University of Georgia ^*  (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Analgesia; Anandamide; Cannabinoids; Endocannabinoids; Opioids; Pain; Primary afferent neurone

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CAPSAZEPINE; CELECOXIB; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DICLOFENAC; ENZYME INHIBITOR; FLURBIPROFEN; IBUPROFEN; KETOROLAC; LUMIRACOXIB; MELOXICAM; METHYL ARACHIDONYL FLUOROPHOSPHONATE; NALTREXONE; NIMESULIDE; OPIATE RECEPTOR; RESVERATROL; ROFECOXIB; UNCLASSIFIED DRUG; URB 602; AMIDE; ANALGESIC AGENT; ARACHIDONIC ACID DERIVATIVE; CANNABINOID; CANNABINOID RECEPTOR; ENDOCANNABINOID;

ANALGESIA; ARTICLE; DERMIS; DRUG EFFICACY; EPIDERMIS; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SENSORY NERVE; ANIMAL; METABOLISM; PAIN ASSESSMENT; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANALGESICS; ANIMALS; ARACHIDONIC ACIDS; CANNABINOIDS; ENDOCANNABINOIDS; PAIN MEASUREMENT; POLYUNSATURATED ALKAMIDES; RECEPTORS, CANNABINOID; RECEPTORS, OPIOID; SIGNAL TRANSDUCTION;

EID: 75849138241     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467210902010134     Document Type: Article

References (89)

1. Burkitt, H. G.; Young, B.; Daniels, V. G., Eds. Histologie fonctionnelle; Arnette: Paris, 1993.
2. Winkelmann, R. K. Cutaneous sensory nerves. Semin. Dermatol. 1988, 7, 236-268.
3. Kelly, E. J.; Terenghi, G.; Hazari, A.; Wiberg, M. Nerve fibre and sensory end organ density in the epidermis and papillary dermis of the human hand. Br. J. Plast. Surg. 2005, 58, 774-779.
4. Woolf, C. J.; Ma, Q. Nociceptors--noxious stimulus detectors. Neuron 2007, 55, 353-364.
5. Farquhar-Smith, W. P.; Rice, A. S. C. Peripheral mechanisms of inflammatory pain: towards the discovery of novel analgesics. In Recent advances in anaesthesia and analgesia; Adams, A. P. and Cashman, J. N., Eds.; Chur-chill Livingstone: London, 2000, pp. 41-60.
6. Roosterman, D.; Goerge, T.; Schneider, S. W.; Bunnett, N. W.; Steinhoff, M. Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol. Rev. 2006, 86, 1309-1379.
7. Steinhoff, M.; Ständer, S.; Seeliger, S.; Ansel, J. C.; Schmelz, M.; Luger, T. Modern aspects of cutaneous neurogenic inflammation. Arch. Dermatol. 2003, 139, 1479-1488.
8. Di Marzo, V. A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Trends Pharmacol. Sci. 2006, 27, 134-140.
9. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258, 1946-1949.
10. Mechoulam, R.; Ben-Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N. E.; Schatz, A. R.; Gopher, A.; Almog, S.; Martin, B. R.; Compton, D. R.; Pertwee, R. G.; Griffin, G.; Bayewitch, M.; Barg, J.; Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 1995, 50, 83-90.
11. Pertwee, R. G. Cannabinoid receptors and pain. Prog. Neurobiol. 2001, 63, 569-611.
12. Iversen, L.; Chapman, V. Cannabinoids: a real prospect for pain relief? Curr. Opin. Pharmacol. 2002, 2, 50-55.
13. Pestonjamasp, V. K.; Burstein, S. H. Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. Biochim. Biophys. Acta 1998, 1394, 249-260.
14. Piomelli, D.; Beltramo, M.; Giuffrida, A.; Stella, N. Endogenous cannabinoid signaling. Neurobiol. Dis. 1998, 5, 462-473.
15. Bisogno, T.; Howell, F.; Williams, G.; Minassi, A.; Cascio, M. G.; Ligresti, A.; Matias, I.; Schiano-Moriello, A.; Paul, P.; Williams, E.J.; Gangadharan, U.; Hobbs, C.; Di Marzo, V.; Doherty, P. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell. Biol. 2003, 163, 463-468.
16. Di Marzo, V.; Bisogno, T.; De Petrocellis, L.; Melck, D.; Orlando, P.; Wagner, J. A.; Kunos, G. Biosynthesis and inactivation of the endocannabinoid 2- arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Bio- chem. 1999, 264, 258-267.
17. Cravatt, B. F.; Giang, D. K.; Mayfield, S. P.; Boger, D. L.; Lerner, R. A.; Gilula, N. B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384, 83-87.
18. Dinh, T. P.; Carpenter, D.; Leslie, F. M.; Freund, T. F.; Katona, I.; Sensi, S. L.; Kathuria, S.; Piomelli, D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA 2002, 99, 10819-10824.
19. Alexander, S. P.; Kendall, D. A. The complications of promiscuity: endocannabinoid action and metabolism. Br. J. Pharmacol. 2007, 152, 602-623.
20. Jhaveri, M. D.; Richardson, D.; Chapman, V. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br. J. Pharmacol. 2007, 152, 624-632.
21. Guindon, J.; Hohmann, A. G. A physiological role for endocannabinoid-derived products of cyclooxygenase-2-mediated oxidative metabolism. Br. J. Pharmacol. 2008, 153, 1341-1343.
22. Liu, J.; Wang, L.; Harvey-White, J.; Huang, B. X.; Kim, H. Y.; Luquet, S.; Palmiter, R. D.; Krystal, G.; Rai, R.; Mahadevan, A.; Razdan, R. K.; Kunos, G. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 2008, 54, 1-7.
23. Fowler, C. J. The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action. Br. J. Pharmacol. 2007, 152, 594-601.
24. Snider, N. T.; Kornilov, A. M.; Kent, U. M.; Hollenberg, P. F. Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides. J. Pharmacol. Exp. Ther. 2007, 321, 590-597.
25. Martin, W. J.; Patrick, S. L.; Coffin, P. O.; Tsou, K.; Walker, J. M. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci. 1995, 56, 2103-2109.
26. Hohmann, A. G.; Herkenham, M. Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse 2000, 37, 71-80.
27. Hohmann, A. G. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem. Phys. Lipids 2002, 121, 173-190.
28. Millns, P. J.; Chapman, V.; Kendall, D. A. Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones. Br. J. Pharmacol. 2001, 132, 969-971.
29. Ross, R. A.; Coutts, A. A.; McFarlane, S. M.; Anavi-Goffer, S.; Irving, A. J.; Pertwee, R. G.; MacEwan, D. J.; Scott, R. H. Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology 2001, 40, 221-232.
30. Walczak, J. S.; Pichette, V.; Leblond, F.; Desbiens, K.; Beaulieu, P. Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. Neuroscience 2005, 132, 1093-1102.
31. Hohmann, A. G.; Herkenham, M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 1999, 90, 923-931.
32. Hohmann, A. G.; Herkenham, M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 1999, 92, 1171-1175.
33. Ahluwalia, J.; Urban, L.; Capogna, M.; Bevan, S.; Nagy, I. Cannabinoid 1 receptors are expressed in nocceptive primary sensory neurons. Neuroscience 2000, 100, 685-688.
34. Ständer, S.; Schmelz, M.; Metze, D.; Luger, T.; Rukwied, R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J. Dermatol. Sci. 2005, 38, 177-188.
35. Ibrahim, M. M.; Porreca, F.; Lai, J.; Albrecht, P. J.; Rice, F. L.; Khodorova, A.; Davar, G.; Makriyannis, A.; Vanderah, T. W.; Mata, H. P.; Malan, T. P. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc. Natl. Acad. Sci. USA 2005, 102, 3093-3098.
36. Casanova, M. L.; Blazquez, C.; Martinez-Palacio, J.; Villanueva, C.; Fernandez-Acenero, M. J.; Huffman, J. W.; Jorcano, J. L.; Guzman, M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest. 2003, 111, 43-50.
37. Burns, T. L.; Ineck, J. R. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann. Pharmacother. 2006, 40, 251-260.
38. Grimsey, N. L.; Goodfellow, C. E.; Scotter, E. L.; Dowie, M. J.; Glass, M.; Graham, E. S. Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal! J. Neurosci. Methods 2008, 171, 78-86.
39. Jonsson, K. O.; Holt, S.; Fowler, C. J. The endocannabinoid system: current pharmacological research and therapeutic possibilities. Basic Clin. Pharmacol. Toxicol. 2006, 98, 124-134.
40. Calignano, A.; La Rana, G.; Giuffrida, A.; Piomelli, D. Control of pain initiation by endogenous cannabinoids. Nature 1998, 394, 277-281.
41. Richardson, J. D.; Kilo, S.; Hargreaves, K. M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998, 75, 111-119.
42. Conti, S.; Costa, B.; Colleoni, M.; Parolaro, D.; Giagnoni, G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br. J. Pharmacol. 2002, 135, 181-187.
43. Guindon, J.; De Léan, A.; Beaulieu, P. Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal antiinflammatory drug, in acute and inflammatory pain. Pain 2006, 121, 85-93.
44. Guindon, J.; Lo Verme, J.; De Léan, A.; Piomelli, D.; Beaulieu, P. Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: A role for endogenous fatty-acid ethanolamides? Eur. J. Pharmacol. 2006, 550, 68-77.
45. Guindon, J.; Desroches, J.; Beaulieu, P. The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br. J. Pharmacol. 2007, 150, 693-701.
46. Li, J.; Daughters, R. S.; Bullis, C.; Bengiamin, R.; Stucky, M. W.; Brennan, J.; Simone, D. A. The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain 1999, 81, 25-33.
47. Nackley, A. G.; Suplita, R. L., 2nd; Hohmann, A. G. A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 2003, 117, 659-670.
48. Nackley, A. G.; Makriyannis, A.; Hohmann, A. G. Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 2003, 119, 747-757.
49. Quartilho, A.; Mata, H. P.; Ibrahim, M. M.; Vanderah, T. W.; Porreca, F.; Makriyannis, A.; Malan, T. P., Jr. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 2003, 99, 955-960.
50. Hohmann, A. G.; Farthing, J. N.; Zvonok, A. M.; Makriyannis, A. Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J. Pharmacol. Exp. Ther. 2004, 308, 446-453.
51. Lo Verme, J.; Fu, J.; Astarita, G.; La Rana, G.; Russo, R.; Calignano, A.; Piomelli, D. The nuclear receptor peroxisome proliferator-activated receptoralpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 2005, 67, 15-19.
52. Lo Verme, J.; Russo, R.; La Rana, G.; Fu, J.; Farthing, J.; Mattace-Raso, G.; Meli, R.; Hohmann, A.; Calignano, A.; Piomelli, D. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptoralpha. J. Pharmacol. Exp. Ther. 2006, 319, 1051-1061.
53. Maccarrone, M.; Bari, M.; Battista, N.; Finazzi-Agro, A. Endocannabinoid degradation, endotoxic shock and inflammation. Curr. Drug Targets Inflamm. Allergy 2002, 1, 53-63.
54. Liu, J.; Batkai, S.; Pacher, P.; Harvey-White, J.; Wagner, J. A.; Cravatt, B. F.; Gao, B.; Kunos, G. Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phospho-inositide 3-kinase/NF-kappaB independently of platelet-activating factor. J. Biol. Chem. 2003, 278, 45034-45039.
55. Liu, J.; Wang, L.; Harvey-White, J.; Osei-Hyiaman, D.; Razdan, R.; Gong, Q.; Chan, A. C.; Zhou, Z.; Huang, B. X.; Kim, H. Y.; Kunos, G. A biosynthetic pathway for anandamide. Proc. Natl. Acad. Sci. USA 2006, 103, 13345-13350.
56. Malan, T. P.; Ibrahim, M. M.; Vanderah, T. W.; Makriyannis, A.; Porreca, F. Inhibition of pain responses by activation of CB(2) cannabinoid receptors. Chem. Phys. Lipids 2002, 121, 191-200.
57. Fowler, C. J.; Stenstrom, A.; Tiger, G. Ibuprofen inhibits the metabolism of the endogenous cannabimimetic agent anandamide. Pharmacol. Toxicol. 1997, 80, 103-107.
58. Fowler, C. J.; Janson, U.; Johnson, R. M.; Wahlstrom, G.; Stenstrom, A.; Norstrom, K.; Tiger, G. Inhibition of anandamide hydrolysis by the enantiomers of ibuprofen, ketorolac, and flurbiprofen. Arch. Biochem. Biophys. 1999, 362, 191-196.
59. Torres-Lopez, J. E.; Ortiz, M. I.; Castaneda-Hernandez, G.; Alonso-Lopez, R.; Asomoza-Espinosa, R.; Granados-Soto, V. Comparison of the antinociceptive effect of celecoxib, diclofenac and resveratrol in the formalin test. Life Sci. 2002, 70, 1669-1676.
60. Islas-Cadena, M.; Aguirre-Banuelos, P.; Granados-Soto, V. (1999) Evidence for the participation of the nitric oxide-cyclic GMP pathway in the antinociceptive effect of nimesulide. J. Pharmacol. Toxicol. Methods 1999, 42, 87-92.
61. Aguirre-Banuelos, P.; Granados-Soto, V. Evidence for the participation of the nitric oxide-cyclic GMP pathway in the antinociceptive action of meloxicam in the formalin test. Eur. J. Pharmacol. 2000, 395, 9-13.
62. Lozano-Cuenca, J.; Castaneda-Hernandez, G.; Granados-Soto, V. Peripheral and spinal mechanisms of antinociceptive action of lumiracoxib. Eur. J. Pharmacol. 2005, 513, 81-91.
63. Francischi, J. N.; Chaves, C. T.; Moura, A. C.; Lima, A. S.; Rocha, O. A.; Ferreira-Alves, D. L.; Bakhle, Y. S. Selective inhibitors of cyclo-oxygenase- 2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. Br. J. Pharmacol. 2002, 137, 837-844.
64. Ates, M.; Hamza, M.; Seidel, K.; Kotalla, C. E.; Ledent, C.; Gühring, H. Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test. Eur. J. Neurosci. 2003, 17, 597-604.
65. Jayamanne, A.; Greenwood, R.; Mitchell, V.A.; Aslan, S.; Piomelli, D.; Vaughan, C. W. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br. J. Pharmacol. 2005, 147, 281-288.
66. Hohmann, A. G.; Suplita, R. L.; Bolton, N. M.; Neely, M. H.; Fegley, D.; Mangieri, R.; Krey, J. F.; Walker, J. M.; Holmes, P. V.; Crystal, J. D.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; Piomelli, D. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005, 435, 1108-1112.
67. Caterina, M. J.; Schumacher, M. A.; Tominaga, M.; Rosen, T. A.; Levine, J. D.; Julius, D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389, 816-824.
68. Di Marzo, V.; Bisogno, T.; De Petrocellis, L. Anandamide: some like it hot. Trends Pharmacol. Sci. 2001, 22, 346-349.
69. Piomelli, D. The ligand that came from within. Trends Pharmacol. Sci. 2001, 22, 17-19.
70. Ross, R. A. Anandamide and vanilloid TRPV1 receptors. Br. J. Pharmacol. 2003, 140, 790-801.
71. Di Marzo, V.; Blumberg, P. M.; Szallasi, A. Endovanilloid signaling in pain. Curr. Opin. Neurobiol. 2002, 12, 372-379.
72. Malan, T. P., Jr.; Porreca, F. Lipid mediators regulating pain sensitivity. Prostaglandins Other Lipid Mediat. 2005, 77, 123-130.
73. Cristino, L.; De Petrocellis, L.; Pryce, G.; Baker, D.; Guglielmotti, V.; Di Marzo, V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 2006, 139, 1405-1415.
74. Bolcskei, K.; Helyes, Z.; Szabo, A.; Sandor, K.; Elekes, K.; Nemeth, J.; Almasi, R.; Pinter, E.; Petho, G.; Szolcsanyi, J. Investigation of the role of TRPV1 receptors in acute and chronic nociceptive processes using genedeficient mice. Pain 2005, 117, 368-376.
75. Premkumar, L. S.; Ahern, G. P. Induction of vanilloid receptor channel activity by protein kinase C. Nature 2000, 408, 985-990.
76. Ahern, G. P. Activation of TRPV1 by the satiety factor oleoylethanolamide. J. Biol. Chem. 2003, 278, 30429-30434.
77. McMahon, S. B.; Cafferty, W. B.; Marchand, F. Immune and glial cell factors as pain mediators and modulators. Exp. Neurol. 2005, 192, 444-462.
78. Galoyan, S. M.; Petruska, J. C.; Mendell, L. M. Mechanisms of sensitization of the response of single dorsal root ganglion cells from adult rat to noxious heat. Eur. J. Neurosci. 2003, 18, 535-541.
79. Farquhar-Smith, W. P.; Jaggar, S. I.; Rice, A. S. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain 2002, 97, 11-21.
80. Rice, A. S.; Farquhar-Smith, W. P.; Nagy, I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot. Essent. Fatty Acids 2002, 66, 243-256.
81. Horigome, K.; Pryor, J. C.; Bullock, E. D.; Johnson, E. M., Jr. Mediator release from mast cells by nerve growth factor. Neurotrophin specificity and receptor mediation. J. Biol. Chem. 1993, 268, 14881-14887.
82. Woolf, C. J.; Ma, Q. P.; Allchorne, A.; Poole, S. (1996) Peripheral cell types contributing to the hyperalgesic action of nerve growth factor in inflammation. J. Neurosci. 1996, 16, 2716-2723.
83. Costa, B.; Siniscalco, D.; Trovato, A. E.; Comelli, F.; Sotgiu, M. L.; Colleoni, M.; Maione, S.; Rossi, F.; Giagnoni, G. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br. J. Pharmacol. 2006, 148, 1022-1032.
84. Massi, P.; Vaccani, A.; Parolaro, D. Cannabinoids, immune system and cytokine network. Curr. Pharm. Des. 2006, 12, 3135-3146.
85. Pugh, G. Jr.; Mason, D. J., Jr.; Combs, V.; Welch, S. P. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord. J. Pharmacol. Exp. Ther. 1997, 281, 730-737.
86. Houser, S. J.; Eads, M.; Embrey, J. P.; Welch, S. P. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide. Brain Res. 2000, 857, 337-342.
87. Tham, S. M.; Angus, J. A.; Tudor, E. M.; Wright, C. E. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice. Br. J. Pharmacol. 2005, 144, 875-884.
88. Williams, I. J.; Edwards, S.; Rubo, A.; Haller, V. L.; Stevens, D. L.; Welch, S. P. Time course of the enhancement and restoration of the analgesic efficacy of codeine and morphine by delta9-tetrahydrocannabinol. Eur. J. Pharmacol. 2006, 539, 57-63.
89. França, D. S.; Ferreira-Alves, D. L.; Duarte, I. D.; Ribeiro, M. C.; Rezende, R. M.; Bakhle, Y. S.; Francischi, J. N. Endogenous opioids mediate the hypoalgesia induced by selective inhibitors of cyclo-oxygenase 2 in rat paws treated with carrageenan. Neuropharmacology 2006, 51, 37-43.